Tumor Animal Models: MRI and MRS

Hall C
Wednesday: 13:30 – 15:30

1025.   Diffusion Weighted MR Imaging Improves Prostate Tumor Detection in Transgenic Mice:
A Comparison of T2 and Apparent Diffusion Coefficients in Normal Prostate and Tumor,
S-K. Song, Z. Qu, J. Milbrandt, E.M. Garabedian, J.I. Gordon and J.J.H. Ackerman, Washington University, St. Louis, MO, USA.
1026.  HGF/SF-Induced Hemodynamic Activity in Breast Tumor Tissue: A New MRI Diagnostic and Prognostic Tool, R. Abramovitch, T. Kushnir, G. Tsarfaty, M. Shaharabany, R. Ron, J. Horev, M. Ravid, I. Itzchak and I. Tsarfaty, Sheba Medical Center, Tel-Hashomer, Israel; Tel Aviv University, Tel Aviv, Israel and fBIT LTD, Tel-Hashomer Israel.
1027.  Validiation of TmDOTP5- as an In Vivo ²³Na NMR Shift Reagent in 9L Gliosarcoma, P.M. Winter, H. Poptani and N. Bansal, University of Pennsylvania, Philadelphia, PA, USA.
1028.  Characterisation of the Development of Hepatic Tumours in an Experimental Animal Model Using
In Vivo Image-guided ¹H-MRS,
L.M. Foley, R.A. Towner, P. Russell and D.M. Painter, James Cook University, Townsville, Queensland, Australia and Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
1029.  ¹H Magnetic Resonance Spectroscopic Imaging of Extracellular pH in an Intracerebral Glioma, M.L. Garcia-Martin, G. Hérigault, C. Rémy, R. Farion, P. Ballesteros, J.A. Coles, S. Cerdan and A. Ziegler, Instituto de Investigaciones Biomédicas, Madrid, Spain and Centre Hospitalier Universitaire, Grenoble, France.
1030.  Evaluation of a and g-folate isomers of Gd-DO3A-APA-folate in Folate-Receptor Positive KB Cells and Implanted Tumors: Unexpected Binding Affinity for the a-isomer, P. Wedeking, K. Ramalingam, R. Pillai, T. Arunachalam, K. Linder, J. Johnstone, S. Eaton, R.E. Wager, R. Shukla, A.D. Nunn and M.F. Tweedle, Bracco Research USA, Princeton, NJ, USA.
1031.  Enhancement of Hyperglycemia-Induced Acidification by Meta-Iodobenzylguanidine: Differential Response in Human Melanoma Xenografts and Normal Tissues, R. Zhou, N. Bansal, D.B. Leeper and J.D. Glickson, University of Pennsylvania and Thomas Jefferson University, Philadelphia, PA, USA.
1032.  Drug Targeting: Monitoring of a Drug-Carrier System by Means of Metabolic Fluorine-19 NMR Imaging, M.E. Bellemann, A. Schlicker, H. Sinn, G. Brix and P. Peschke, University of Applied Sciences, Jena, Germany and German Cancer Research Center (dkfz), Heidelberg, Germany.
1033.  19F NMR As a Tool to Measure the Efficiency of Adenoviral CD Gene Transfer. In Vitro and In Vivo Monitoring of 5-FC to 5-FU Conversion, P. Kiss, A. Gustin, D. Buchsbaum, T. Simor, L. Lenard, S. Vickers and G.A. Elgavish, University of Alabama, Birmingham, AL, USA.
1034.  MRI Assessment of Chemoembolization of Liver Tumors in a Rabbit Model, D. Artemov, C. Magee, S. Abraham, Z. Bhujwalla and J.F. Geschwind, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
1035.  Phosphomonoester Levels in Drug Resistant and Drug Sensitive Human Breast Cancer Xenografts via Fully-Relaxed ³¹P MRS, D.L. Morse, N. Raghunand, B. Baggett, R.J. Gillies and N.R. Aiken, University of Arizona Cancer Center, Tucson, AZ, USA.
1036.  Validation of a Snapshot FLASH Protocol for Rapid Assessment of Contrast Enhancement to Monitor Tumour Therapy, B. Morgan, A. Jivan, M.A. Horsfield, M. Buechert, J. Hennig and G.R. Cherryman, University of Leicester, Leicester, UK and University of Freiburg, Freiburg, Germany.
1037. ¹H Metabolic Response of the CWR22 Prostate Tumor Xenograft Following 20 Gy Radiation Studied by BASSALE SI, J.P. Dyke, C. Matei, Y. Chen, D.C. Shungu, J.A. Koutcher and K.L. Zakian, Memorial Sloan-Kettering Cancer Center and Columbia University, New York, NY, USA.
1038.  Cyclophosphamide Treatment of RIF-1 Tumors: Early Detection of therapeutic Response by T2 and T1r MRI, H. Poptani, U. Duvvuri, L.N. Desbarats, M. Feldman, R. Reddy, J.S. Leigh and J.D. Glickson, University of Pennsylvania, Philadelphia, PA, USA.
1039.  Regional Tumor Tissue pO2 and Blood sO2: Comparison of 19F MR EPI and Frequency Domain NIR Spectroscopy, Y. Song, X. Jiang, D. Zhao, A. Constantinescu, H. Liu and R.P. Mason, University of Texas Southwestern Medical Center, Dallas, TX, USA.
1040.  Tumor Oximetry: Comparison of 19F MR EPI (FREDOM) and the Fiber-Optic OxyLite™, R.P. Mason, D. Zhao, A. Constantinescu and A. Obeid, University of Texas Southwestern Medical Center, Dallas, TX, USA and Oxford Optronix, Oxford, UK.
1041.  19F MRS Measurement of Tumour Pharmacokinetics of SR4554, a 2-Nitroimidazole Hypoxia Probe, B.M. Seddon, R.J. Maxwell, D.J. Honess, R. Grimshaw, F. Raynaud and P. Workman, Institute of Cancer Research, Sutton, Surrey, UK and Gray Laboratory Cancer Research Trust, Northwood, Middlesex, UK.
1042.  On the Correlation of FLOOD/MGRE Imaging and Dynamic Contrast Agent Imaging With Dimeglumine Gadopentetate (Magnevist), D.J.O. McIntyre, S.P. Robinson and J.R. Griffiths, St George's Hospital, London, UK.
1043.  100% N2 Breathing Causes Vascular Collapse in Some Subcutaneous Tumors, F.A. Howe, S.P. Robinson and J.R. Griffiths, St George's Hospital Medical School, London, UK.
1044.  Measurement of Spectrally Inhomogeneous BOLD Contrast Changes Using High Spectral and Spatial Resolution (HiSS) MRI, H.A. Al-Hallaq, M.A. Zamora, A. Farrel and G.S. Karczmar, University of Chicago, Chicago, IL, USA.
1045.  Effects of Glucose on BOLD Contrast in Tumors During Normoxia and Hyperoxia, G.S. Karczmar, H.A. Al-Hallaq and M.A. Zamora, University of Chicago, Chicago, IL, USA.
1046.  Relative Roles of O2 and CO2 in the Carbogen-Enhanced-Uptake of Ifosfamide into Tumours - an in Vivo ³¹P MRS Study, L.M. Rodrigues, S.P. Robinson, P.M.J. McSheehy, M. Stubbs and J.R. Griffiths, St. George's Hospital Medical School, London, UK.
1047.  An MR Imaging and Spectroscopic Comparison In Vivo of Mouse Hepa-1 Wild-Type Tumors and Tumors Deficient in Hypoxia-Inducible-Factor-1b (HIF-1b), J.R. Griffiths, P.M.J. McSheehy, S.P. Robinson, H. Troy, D. Jackson, M. Stubbs, P.J. Ratcliffe and A. Harris, St. George's Hospital Medical School, London, UK; AstraZeneca, Cheshire, UK and John Radcliffe Hospital, Oxford, UK.
1048.  Comparison of T1 and T2* Enhancement in MNU Chemically-Induced Mammary Carcinomas After Administration of the Blood Pool Agent NC100150 Injection, D.J.O. McIntyre, S.P. Robinson, K. Tarlo and J.R. Griffiths, St George's Hospital Medical School, London, UK and Nycomed Imaging, Wayne, PA, USA.
1049.  Dynamic MRI of Osteosarcoma Xenografts: The Effect of an Intratumoural Hyaluronidase Injection on the Tumour Water Diffusion and Blood Volume, M.H. Hjelstuen, O. Haraldseth, C. Davies, I.S. Gribbestad, A. Bjørnerud and C. Brekken, SINTEF Unimed and The Norwegian University of Science and Technology, Trondheim, Norway and Nycomed Imaging AS, Oslo, Norway.
1050.  Visualization of Subcutaneous Lymphatics by Contrast Enhanced MRI, H. Dafni, B. Shechter and M. Neeman, The Weizmann Institute of Science, Rehovot, Israel.
1051.  Tracking the Interstitial Movement of a Macromolecular Contrast Agent, D. Artemov, M. Solaiyappan, M. Neeman and Z.M. Bhujwalla, The Johns Hopkins University School of Medicine, Baltimore, MD, USA and The Weizmann Institute of Science, Rehovot, Israel.
1052.  The Reptation Mechanism in Tumor Imaging, E.E. Uzgiris and A. Bogdanov, Jr., General Electric Research & Development, Schenectady, NY, USA and Massachusetts General Hospital, Charlestown, MA, USA.
1053.  Selective Thrombosis of Tumor Vessels for Cancer Therapy: The Induced Blood Coagulation and Lysis Measured by MRI, M-Y. Su, H. Yu, M.K. Samoszuk and O. Nalcioglu, University of California, Irvine, CA, USA and Quest Diagnostics Inc., CA, USA.
1054.  MRI Macromolecular Contrast Agents as Indicators of Tumor Starvation, K. Beravs, T. Ivanu¹a, G. Ser¹a, M. Èemaar, V. Jevtiè and F. Demsar, Institute Jozef Stefan, University of Ljubljana, Institute of Oncology and Medical Center, University of Ljubljana, Ljubljana, Slovenia.
1055.  Is There an Association Between Systemic VEGF and Permeability In Locally Advanced Rectal Adenocarcinoma? Initial Observations, A.S.K. Dzik-Jurasz, M. George, A. Padhani, R.I. Swift, M.O. Leach and I.J. Rowland, Royal Marsden NHS Trust, Sutton, UK and Mayday University Hospital, Surrey, UK.
1056.  Use of Dynamic MRI to Assess Effect of Combretastatin A4 Phosphate (CA4P) on Tumour and Normal Tissue Blood Flow in Rats and Humans, S.M. Galbraith, N.J. Taylor, R. Maxwell, G.J.S. Rustin, H. Baddeley, I. Wilson, V. Prise and G. Tozer, Mount Vernon Hospital and Gray Laboratory, Northwood, Middlesex, UK.
1057.   Assessment of the Relative Cerebral Blood Volumes in Various Brain Tumors by Using CBV Mapping, J-J. Seo, E.H. Ko, H-K. Kang, G-W. Jeong, H-J. Kim, J-G. Park and Y-H. Kim, Chonnam University Hospital, Kwang-Ju, Korea.
1058.   Abnormal Retinal Angiogenesis is Strongly Associated with a Subnormal MRI Panretinal Oxygenation Response: Effect of 28% Supplemental Oxygen Treatment, B.A. Berkowitz and W. Zhang, Wayne State University School of Medicine, Detroit, MI, USA.
1059.   Examination of vx2-Tumors Using a 2-Pool Model With Proton Exchange and Dynamic Gd-DTPA Enahanced MRI, M.D. Noseworthy, X. Qi, J.A. Stainsby and G.A. Wright, University of Toronto and Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada.
1060.   WITHDRAWN.
1061.   Accurate Measurement of Absolute Fractional Blood Volume for the Evaluation of Tumor Angiogenesis, Y.R. Kim and K.M. Donahue, Medical College of Wisconsin, Milwaukee, WI, USA.
1062.   Application of a Blood Pool Agent NC100150 for Tumor Characterization: The Optimal Pulse Sequence and Dose Accumulative Effects, M-Y. Su and O. Nalcioglu, University of California, Irvine, CA, USA.
1063.   Combined Proton Spectroscopic and Vascular Imaging of Prostate Cancer Models, Z.M. Bhujwalla and D. Artemov, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
1064.   CBF and CBV are Mismatched in Rat Model of Human Glioma, S.D. Packard, T. Ichikawa, J.B. Mandeville, E.A. Chiocca, B.R. Rosen and J.J.A. Marota, Massachusetts General Hospital, Charlestown, MA, USA.
1065.   Magnetic Resonance Imaging of Tumor Permeability and Blood Volume: Non-Invasive Markers for the Efficacy of PTK 787 on Tumor Vasculature, M. Rudin, D. Baumann, C.R. Schnell and J.M. Wood, Novartis Pharma AG, Basel, Switzerland.

Return to ISMRM program